| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Marco Donia | Q40146733 |
| James A. McCubrey | Q42317570 | ||
| Paolo Fagone | Q42417734 | ||
| Camilla Evangelisti | Q57233682 | ||
| Richard A. Franklin | Q68547480 | ||
| Ferdinando Nicoletti | Q84521195 | ||
| Massimo Libra | Q37842996 | ||
| P2093 | author name string | A M Martelli | |
| F Nicoletti | |||
| V Ruvolo | |||
| P Ruvolo | |||
| J Bäsecke | |||
| L S Steelman | |||
| S L Abrams | |||
| C R Kempf | |||
| F Stivala | |||
| W Chappell | |||
| P2860 | cites work | The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner | Q21629049 |
| Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling | Q22003910 | ||
| The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity | Q24293101 | ||
| Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function | Q24294552 | ||
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade | Q24311840 | ||
| Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms | Q24312029 | ||
| Regulation of RKIP binding to the N-region of the Raf-1 kinase | Q24314069 | ||
| Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 | Q24532154 | ||
| Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation | Q24534094 | ||
| Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation | Q24548297 | ||
| JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis | Q24554008 | ||
| Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein | Q24554247 | ||
| Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells. | Q38311150 | ||
| Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein | Q38358298 | ||
| Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors | Q39457731 | ||
| The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro | Q39640407 | ||
| IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia | Q39673732 | ||
| Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway | Q39892705 | ||
| Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins | Q39900720 | ||
| Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis | Q39952595 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. | Q40024347 | ||
| Regulation of tumor cell sensitivity to TRAIL-induced apoptosis by the metastatic suppressor Raf kinase inhibitor protein via Yin Yang 1 inhibition and death receptor 5 up-regulation. | Q40073029 | ||
| A hidden oncogenic positive feedback loop caused by crosstalk between Wnt and ERK pathways. | Q40181009 | ||
| Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma | Q40200306 | ||
| Molecular pathways leading to oxidative stress-induced phosphorylation of Akt. | Q40229670 | ||
| Syk-dependent mTOR activation in follicular lymphoma cells. | Q40243215 | ||
| Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis | Q40358926 | ||
| Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. | Q40462629 | ||
| Regulation of Raf-1 by direct feedback phosphorylation. | Q40467820 | ||
| MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol | Q40537978 | ||
| Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors | Q40540288 | ||
| RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis | Q40591753 | ||
| Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation | Q40635020 | ||
| Effects of inducible MEK1 activation on the cytokine dependency of lymphoid cells | Q40804306 | ||
| Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism | Q40887173 | ||
| A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells. | Q40896676 | ||
| Paradoxical activation of Raf by a novel Raf inhibitor | Q40939473 | ||
| Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells | Q40989764 | ||
| RAF translocations expand cancer targets | Q42572365 | ||
| Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia | Q42742064 | ||
| The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene | Q42827990 | ||
| Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. | Q42963571 | ||
| A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study | Q43181954 | ||
| The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs | Q43206184 | ||
| Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization | Q43258056 | ||
| A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal | Q43543397 | ||
| Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf | Q44679396 | ||
| FLT3 mutations in childhood acute lymphoblastic leukemia | Q44690047 | ||
| Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia | Q44737477 | ||
| FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins | Q44775125 | ||
| Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia | Q44775999 | ||
| SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways | Q45345641 | ||
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Q46003222 | ||
| Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. | Q46015851 | ||
| Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. | Q46431059 | ||
| Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance | Q46441674 | ||
| Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. | Q46503011 | ||
| Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. | Q46797237 | ||
| Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia | Q46799049 | ||
| Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations. | Q48028205 | ||
| The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. | Q50335942 | ||
| Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. | Q50335943 | ||
| Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene. | Q51903901 | ||
| RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. | Q52002743 | ||
| Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. | Q52576329 | ||
| MNK, EIF4E and targeting translation for therapy. | Q53499743 | ||
| Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. | Q53796172 | ||
| Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia. | Q54653299 | ||
| Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome. | Q54704480 | ||
| Mathematical Modeling of the Influence of RKIP on the ERK Signaling Pathway | Q57711692 | ||
| Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines | Q73171064 | ||
| Mutations of the PTPN11 gene in therapy-related MDS and AML with rare balanced chromosome translocations | Q79850201 | ||
| Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone | Q79984705 | ||
| Reactive oxygen intermediates and signaling through kinase pathways | Q80302410 | ||
| A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia | Q80432945 | ||
| BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias | Q80695687 | ||
| Regulatory phosphorylation of Bim: sorting out the ERK from the JNK | Q81833475 | ||
| Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo | Q24554527 | ||
| Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus | Q24600932 | ||
| Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance | Q24645668 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer | Q27662487 | ||
| MEK1 mutations confer resistance to MEK and B-RAF inhibition | Q27777362 | ||
| Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP | Q28144497 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| The emerging roles of forkhead box (Fox) proteins in cancer | Q28253741 | ||
| Transcriptional regulation by MAP kinases | Q28276533 | ||
| Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis | Q28278590 | ||
| Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase | Q28283499 | ||
| Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G | Q28285121 | ||
| Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia | Q28305210 | ||
| Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder | Q28508406 | ||
| Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5 | Q28577191 | ||
| Insulin receptor substrate-1/SHP-2 interaction, a phenotype-dependent switching machinery of insulin-like growth factor-I signaling in vascular smooth muscle cells | Q28579027 | ||
| MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase | Q28581201 | ||
| Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation | Q28609129 | ||
| Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases | Q28609156 | ||
| Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia | Q29615030 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Coordinating ERK/MAPK signalling through scaffolds and inhibitors | Q29618995 | ||
| Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap | Q33582891 | ||
| Serine/threonine phosphorylation in cytokine signal transduction | Q33818655 | ||
| Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma | Q33992803 | ||
| Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras | Q33993387 | ||
| Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development | Q34069663 | ||
| Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis | Q34109970 | ||
| Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy | Q34306865 | ||
| Lyn Kinase-Dependent Regulation of miR181 and Myeloid Cell Leukemia-1 Expression: Implications for Drug Resistance in Myelogenous Leukemia | Q34309928 | ||
| Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase | Q34407252 | ||
| Phase I study of sorafenib in patients with refractory or relapsed acute leukemias | Q34451540 | ||
| The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies | Q34790644 | ||
| Targeting the leukemic stem cell: the Holy Grail of leukemia therapy | Q37272565 | ||
| MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts | Q37425601 | ||
| FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. | Q37495206 | ||
| Emerging Raf inhibitors. | Q37588717 | ||
| Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. | Q37593642 | ||
| Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics | Q37605160 | ||
| Emerging MEK inhibitors. | Q37691441 | ||
| The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukaemia | Q37692499 | ||
| The role of Bcl-2 family proteins in chronic lymphocytic leukaemia | Q37722988 | ||
| Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response | Q37753517 | ||
| Drug resistance in mutant FLT3-positive AML. | Q37771863 | ||
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies | Q37779489 | ||
| Snail is a repressor of RKIP transcription in metastatic prostate cancer cells | Q38297109 | ||
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | Q38300326 | ||
| Combined effects of aberrant MEK1 activity and BCL2 overexpression on relieving the cytokine dependency of human and murine hematopoietic cells. | Q38311147 | ||
| Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies | Q35020561 | ||
| Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. | Q35075545 | ||
| PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling | Q35227481 | ||
| Conferring specificity on the ubiquitous Raf/MEK signalling pathway | Q35634546 | ||
| Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development | Q35663786 | ||
| The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. | Q35773205 | ||
| 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors | Q35778060 | ||
| The role of Raf kinase inhibitor protein (RKIP) in health and disease | Q35864013 | ||
| Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 | ||
| Dissecting eIF4E action in tumorigenesis | Q36209711 | ||
| Calcium/calmodulin-dependent protein kinases as potential targets in cancer therapy. | Q36219718 | ||
| Further evidence that ribavirin interacts with eIF4E | Q36298008 | ||
| Inherited predispositions and hyperactive Ras in myeloid leukemogenesis | Q36302528 | ||
| Mechanisms of drug inhibition of signalling molecules | Q36488752 | ||
| Raf kinase inhibitor protein regulation of raf and MAPK signaling | Q36498712 | ||
| Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis | Q36562739 | ||
| Activation of the calcium/calmodulin-dependent protein kinases as a consequence of oxidative stress. | Q36598871 | ||
| Phosphatase and feedback regulation of Raf-1 signaling | Q36705960 | ||
| RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation | Q36745240 | ||
| Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events | Q36843531 | ||
| Tumorigenic activity and therapeutic inhibition of Rheb GTPase | Q36843535 | ||
| Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma | Q36980836 | ||
| New modes of translational control in development, behavior, and disease | Q37033136 | ||
| AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance | Q37039117 | ||
| Genetics of therapy-related myelodysplasia and acute myeloid leukemia | Q37058777 | ||
| Targeting the eukaryotic translation initiation factor 4E for cancer therapy | Q37075670 | ||
| Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. | Q37109225 | ||
| Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. | Q37109227 | ||
| (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway | Q37112466 | ||
| Genetic predictors of MEK dependence in non-small cell lung cancer | Q37113682 | ||
| Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas | Q37118264 | ||
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance | Q37152481 | ||
| Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs | Q37192602 | ||
| The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy | Q37192611 | ||
| P433 | issue | 7 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 1080-1094 | |
| P577 | publication date | 2011-04-15 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy | |
| P478 | volume | 25 |
| Q41922615 | A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer. |
| Q36926129 | A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
| Q28541630 | A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells |
| Q41963486 | ADAM17 mediates OSCC development in an orthotopic murine model. |
| Q38184584 | ALK-positive cancer: still a growing entity. |
| Q39463725 | AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. |
| Q36579425 | Acute mitochondrial inhibition by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) 1/2 inhibitors regulates proliferation |
| Q36006358 | Acute myeloid leukemia developing in patients with autoimmune diseases |
| Q41529372 | Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways |
| Q27686983 | Advances in targeting signal transduction pathways |
| Q35798939 | Andrographolide Analogue Induces Apoptosis and Autophagy Mediated Cell Death in U937 Cells by Inhibition of PI3K/Akt/mTOR Pathway |
| Q52947173 | Anti-apoptotic effect of microRNA-30b in early phase of rat myocardial ischemia-reperfusion injury model. |
| Q37410515 | Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. |
| Q42332071 | Arresting kinase suppressor of Ras in an inactive state |
| Q40414164 | Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer |
| Q36866417 | BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors |
| Q64228108 | C14orf159 suppresses gastric cancer cells' invasion and proliferation by inactivating ERK signaling |
| Q53208866 | Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia. |
| Q55342183 | Changes of signal transductivity and robustness of gene regulatory network in the carcinogenesis of leukemic subtypes via microarray sample data. |
| Q54342441 | Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. |
| Q36341451 | Co-clustering phenome-genome for phenotype classification and disease gene discovery |
| Q37540206 | Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin |
| Q38956056 | Concomitant evaluation of PMA+ionomycin-induced kinase phosphorylation and cytokine production in T cell subsets by flow cytometry. |
| Q35640301 | Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells |
| Q54982256 | Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis. |
| Q33736781 | Cracking the cytotoxicity code: apoptotic induction of 10-acetylirciformonin B is mediated through ROS generation and mitochondrial dysfunction |
| Q37602508 | Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway |
| Q37610391 | Distinct signaling programs control human hematopoietic stem cell survival and proliferation. |
| Q28550472 | Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells |
| Q39440247 | Dysregulation of BCL-2 family proteins by leukemia fusion genes |
| Q36556350 | Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine |
| Q55216431 | Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia. |
| Q37031268 | Effects of ectopic expression of NGAL on doxorubicin sensitivity |
| Q58712167 | Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway |
| Q40144087 | Exploring the interplay between autoimmunity and cancer to find the target therapeutic hotspots. |
| Q26785368 | F-box protein interactions with the hallmark pathways in cancer |
| Q39386021 | Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia |
| Q28588720 | Functional redundancy of Sos1 and Sos2 for lymphopoiesis and organismal homeostasis and survival |
| Q36972631 | Gambogic acid induces apoptosis in diffuse large B-cell lymphoma cells via inducing proteasome inhibition |
| Q41884410 | Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains |
| Q104257735 | Growth inhibition and suppression of the mTOR and Wnt/β-catenin pathways in T-acute lymphoblastic leukemia by rapamycin and MYCN depletion |
| Q37576246 | HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway |
| Q92839062 | Hsa_circ_0101996 combined with hsa_circ_0101119 in peripheral whole blood can serve as the potential biomarkers for human cervical squamous cell carcinoma |
| Q31159325 | Identification of protein kinase inhibitors with a selective negative effect on the viability of Epstein-Barr virus infected B cell lines |
| Q42513156 | Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy. |
| Q36413813 | Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene |
| Q49787961 | Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia |
| Q50577882 | Insulin receptor A and Sirtuin 1 synergistically improve learning and spatial memory following chronic salidroside treatment during hypoxia. |
| Q89598332 | Integrin α7 and Extracellular Matrix Laminin 211 Interaction Promotes Proliferation of Acute Myeloid Leukemia Cells and Is Associated with Granulocytic Sarcoma |
| Q35556981 | Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells |
| Q35640228 | Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy |
| Q33402525 | Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets |
| Q37696978 | MEK1 is required for the development of NRAS-driven leukemia |
| Q39246559 | Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization |
| Q36665287 | Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress |
| Q92292857 | Mechanistic interpretation of non-coding variants for discovering transcriptional regulators of drug response |
| Q61447663 | Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of K1.3 potassium channels, AKT and ERK1/2 signaling |
| Q38106675 | Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. |
| Q92838252 | MicroRNA-143 shows tumor suppressive effects through inhibition of oncogenic K-Ras in pituitary tumor |
| Q35515984 | Mini profile of potential anticancer properties of propofol |
| Q38156191 | Molecular pathways and potential therapeutic targets in glioblastoma multiforme |
| Q37460101 | Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. |
| Q35145197 | Multiple model-informed open-loop control of uncertain intracellular signaling dynamics |
| Q42254184 | NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. |
| Q38392667 | Natural course and biology of CML. |
| Q89683082 | New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML) |
| Q36697045 | Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo |
| Q39240059 | Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells |
| Q51747038 | Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia. |
| Q91633218 | Oxymatrine Inhibits Proliferation and Migration of Vulvar Squamous Cell Carcinoma Cells via Attenuation of the RAS/RAF/MEK/ERK Pathway |
| Q28302461 | PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis |
| Q34164683 | PI3K and mTOR signaling pathways in cancer: new data on targeted therapies |
| Q42011584 | PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis |
| Q27011088 | PTEN regulation of ERK1/2 signaling in cancer |
| Q97531406 | Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q39143241 | Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase s |
| Q38227885 | Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting |
| Q34307356 | Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance |
| Q36901497 | Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses |
| Q38049544 | SIAH proteins: critical roles in leukemogenesis |
| Q39441370 | Selective Targeting of RSK Isoforms in Cancer |
| Q36926143 | Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway |
| Q36498356 | Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. |
| Q38952701 | Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition |
| Q38748709 | Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer |
| Q37990881 | Targeting Mnks for cancer therapy |
| Q51418083 | Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor. |
| Q47281250 | Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. |
| Q39004481 | Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer |
| Q39270291 | Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma |
| Q51328396 | The lack of Raf-1 kinase feedback regulation enhances antiapoptosis in cancer cells. |
| Q36103464 | The toll-like receptor 9 agonist, CpG-oligodeoxynucleotide 1826, ameliorates cardiac dysfunction after trauma-hemorrhage |
| Q39212690 | The viral oncogene Np9 acts as a critical molecular switch for co-activating β-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells |
| Q41573365 | Tricetin Induces Apoptosis of Human Leukemic HL-60 Cells through a Reactive Oxygen Species-Mediated c-Jun N-Terminal Kinase Activation Pathway |
| Q34260622 | Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. |
| Q37254508 | Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma |
| Q53120406 | microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. |
| Q39174629 | β-Ionone arrests cell cycle of gastric carcinoma cancer cells by a MAPK pathway |
Search more.